DGAP-News: iovera Treatment for Dynamic Wrinkles Now Approved in Canada

myoscience 

18.07.2013 12:00
---------------------------------------------------------------------------

REDWOOD CITY, Calif., 2013-07-18 12:00 CEST (GLOBE NEWSWIRE) --
iovera?, the world's first toxin-free treatment for dynamic wrinkles utilizing
the body's natural response to cold, has received regulatory approval in
Canada. Developed by myoscience, inc. in California, the iovera? system targets
dynamic forehead wrinkles precisely using Focused Cold Therapy(TM), an advanced
technology that works immediately to temporarily reduce the appearance of
wrinkles without leaving any toxins or chemicals behind in the body. The
treatment is currently available in the European Union and will be available in
Canada soon. 

People who want to treat their forehead wrinkles but are uncomfortable with
previously available treatments now have a new option with the iovera? system. 
The treatment only takes about 20 minutes, and is an exciting new solution for
those who want a quick toxin-free treatment for dynamic wrinkles 

Clint Carnell, CEO of myoscience, can see the excitement that iovera? is
already generating with its launch in the EU. 'We developed iovera? in
partnership with some of the world's leading physicians. There is powerful
consumer demand for iovera? because it offers a wrinkle solution that has no
toxins and no wait for results, so there's no worry for patients about getting
back to their regular lifestyle.' 

An early partner and physician using iovera? in his clinic in Paris, France,
Dr. Patrick Trevidic says: 'I know from experience that there are patients who
have hesitations about using botulinum toxin. They still want to treat their
wrinkles : iovera? for these patients is a more comfortable option because it
injects nothing into the body. It enables me to better serve more of my
patients and is a welcome addition to my aesthetic treatment toolbox. Best of
all the results are seen immediately which is very exciting.' 

About myoscience

Silicon Valley, California-based myoscience is a privately-held medical device
company committed to making its platform technology, Focused Cold Therapy(TM),
the standard of care for the treatment of peripheral nerve conditions. Focused
Cold Therapy is currently approved in Europe and Canada for temporary wrinkle
reduction, temporary pain reduction and treatment of dermatologic conditions.
The myoscience technology has also been cleared in the United States for use in
pain management and general surgical use. For more information, please visit
www.myoscience.com. 

The myoscience logo is available at
http://www.globenewswire.com/newsroom/prs/?pkgid=13581 


         CONTACT: Alexandra Mack
         650-421-0609
         amack@myoscience.com
News Source: NASDAQ OMX



18.07.2013 Dissemination of a Corporate News, transmitted by DGAP - 
a company of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de

---------------------------------------------------------------------------
 
Language:     English
Company:      myoscience
              
               
              United States
Phone:        
Fax:          
E-mail:       
Internet:     
ISIN:         US9902131674
WKN:          
 
End of Announcement                             DGAP News-Service
 
---------------------------------------------------------------------------